Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

20 hours ago

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

20 hours ago

December 07, 2025 16:00 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…

RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherbys Transparency Initiative

1 day ago

New York, NY, Dec. 06, 2025 (GLOBE NEWSWIRE) -- RadiantVibe Capital Consortium today announced the debut of its new Insight…

BI DeFi Launches New Daily Yield Plan as Demand for Accessible Crypto Income Solutions Grows

1 day ago

New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) -- BI DeFi has officially launched its new Daily Yield Plan, expanding…

Humanoid Global Welcomes Marc Theermann, Chief Strategy Officer of Boston Dynamics to its Technical Advisory Committee

1 day ago

December 05, 2025 16:00 ET  | Source: Humanoid Global Holdings Corp. – NOT FOR DISSEMINATION IN THE UNITED STATES OR…

Olympic flame in Rome: IOC President praises Italys warmth and energy

1 day ago

06 December 2025 - When the flame for the Milano Cortina 2026 Olympic Winter Games lit the Piazza del Quirinale, the square in…

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

2 days ago

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

2 days ago

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

2 days ago

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…

MemeMax, MemeCore’s First Perp DEX, Extends MaxPack Event Ahead of January Launch After 400% Network Surge

2 days ago

SEOUL, South Korea, Dec. 6, 2025 /PRNewswire/ -- MemeMax, the first Perp DEX built within the MemeCore ecosystem, has extended…